... SAN DIEGO July 14 /- NuVasive Inc. (Nasda...NuVasive will hold a conference call on Thursday July 24 2008 at 5:3...After the live Web cast the call will remain available on NuVasive's...About NuVasive ...

SAN DIEGO, July 14 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq:
NUVA), a medical device company focused on developing products for
minimally disruptive surgical treatments for the spine, announced today
details relating to its second quarter 2008 earnings announcement, which
will take place on Thursday, July 24, 2008 after the close of the market.

NuVasive will hold a conference call on Thursday, July 24, 2008 at 5:30
p.m. ET / 2:30 p.m. PT to discuss the results. The dial-in numbers are
1-877-407-4018 for domestic callers and 1-201-689-8471 for international. A
live Web cast of the conference call will be available online from the
investor relations page of the Company's corporate Web site at
http://www.nuvasive.com.

After the live Web cast, the call will remain available on NuVasive's
Web site, http://www.nuvasive.com, through August 24, 2008. In addition, a
telephonic replay of the call will be available until August 14, 2008. The
replay dial-in numbers are 1-877-660-6853 for domestic callers and
1-201-612-7415 for international callers. Please use account number 3055
and conference ID number 289122.

About NuVasive

NuVasive is a medical device company focused on the design, development
and marketing of products for the surgical treatment of spine disorders.
The Company's product portfolio is focused on applications in the over $4.2
billion U.S. spine fusion market. The Company's current principal product
offering includes a minimally disruptive surgical platform called Maximum
Access Surgery, or MAS(R), as well as a growing offering of cervical and
motion preservation products.

The MAS platform offers advantages for both patients and surgeons such
as reduced surgery and hospitalization time and faster recovery. MAS
combines three categories of current product offerings: NeuroVision(R) a
proprietary software-driven nerve avoidance system; MaXcess(R) a unique
split-blade design retraction system; and specialized implants, like
SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption
during spine surgery while allowing maximum visualization and surgical
reproducibility. NuVasive's product offering is also focused on cervical
internal fixation products and its R&D pipeline emphasizes both MAS and
motion preservation.

NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other factors
which, if they do not materialize or prove correct, could cause NuVasive's
results to differ materially from historical results or those expressed or
implied by such forward-looking statements. The potential risks and
uncertainties that could cause actual growth and results to differ
materially include, but are not limited to: the uncertain process of
seeking regulatory approval or clearance for NuVasive's products or
devices, including risks that such process could be significantly delayed;
the possibility that the FDA may require significant changes to NuVasive's
products or clinical studies; the risk that products may not perform as
intended and may therefore not achieve commercial success; the risk that
competitors may develop superior products or may have a greater market
position enabling more successful commercialization; the risk that
additional clinical data may call into question the benefits of NuVasive's
products to patients, hospitals and surgeons; and other risks and
uncertainties more fully described in NuVasive's press releases and
periodic filings with the Securities and Exchange Commission. NuVasive's
public filings with the Securities and Exchange Commission are available at
http://www.sec.gov. NuVasive assumes no obligation to update any forward-looking
statement to reflect events or circumstances arising after the date on
which it was made.

(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...

(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness ... targeting the needs of consumers who are incorporating medical marijuana into their wellness ... Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s two ...

(Date:3/27/2017)... 2017 Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting. This recognition ...

(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...

(Date:3/23/2017)... DUBLIN , Mar. 23, 2017 Research ... Anti-Theft System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 8.8% over the next ... This industry report analyzes the market estimates and forecasts for all ...